Trueblood Wealth Management LLC Takes Position in Perspective Therapeutics, Inc. (NYSE:CATX)

Trueblood Wealth Management LLC bought a new position in shares of Perspective Therapeutics, Inc. (NYSE:CATX) in the third quarter, HoldingsChannel.com reports. The institutional investor bought 16,236 shares of the company’s stock, valued at approximately $217,000.

Several other hedge funds have also recently bought and sold shares of the business. Janus Henderson Group PLC acquired a new position in shares of Perspective Therapeutics during the first quarter worth about $15,511,000. Affinity Asset Advisors LLC acquired a new position in Perspective Therapeutics during the 1st quarter worth approximately $6,069,000. Vanguard Group Inc. boosted its holdings in Perspective Therapeutics by 34.6% in the 1st quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after acquiring an additional 4,566,356 shares during the period. Nicholson Wealth Management Group LLC acquired a new stake in Perspective Therapeutics in the third quarter valued at approximately $21,390,000. Finally, Ally Bridge Group NY LLC purchased a new stake in shares of Perspective Therapeutics during the second quarter valued at approximately $3,951,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Stock Down 3.0 %

Shares of NYSE CATX opened at $11.53 on Friday. The firm has a 50 day moving average price of $13.76. Perspective Therapeutics, Inc. has a twelve month low of $2.20 and a twelve month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last issued its earnings results on Monday, August 12th. The company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.04. The business had revenue of $0.53 million for the quarter. On average, equities analysts forecast that Perspective Therapeutics, Inc. will post -0.87 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Royal Bank of Canada lowered their price target on shares of Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating for the company in a report on Friday, August 16th. Wedbush reaffirmed an “outperform” rating and set a $20.00 target price on shares of Perspective Therapeutics in a research report on Thursday. UBS Group initiated coverage on Perspective Therapeutics in a report on Thursday. They issued a “buy” rating and a $20.00 price target for the company. Bank of America began coverage on Perspective Therapeutics in a report on Thursday, July 25th. They set a “buy” rating and a $24.00 price objective on the stock. Finally, Truist Financial started coverage on Perspective Therapeutics in a research report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 target price on the stock. Ten equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $20.63.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.